Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $5.6 million.

  • BioRestorative Therapies' Liabilities and Shareholders Equity fell 6128.12% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.8 million, marking a year-over-year decrease of 3997.95%. This contributed to the annual value of $12.3 million for FY2024, which is 263.18% down from last year.
  • Latest data reveals that BioRestorative Therapies reported Liabilities and Shareholders Equity of $5.6 million as of Q3 2025, which was down 6128.12% from $8.5 million recorded in Q2 2025.
  • Over the past 5 years, BioRestorative Therapies' Liabilities and Shareholders Equity peaked at $22.5 million during Q4 2021, and registered a low of $2.2 million during Q3 2021.
  • For the 5-year period, BioRestorative Therapies' Liabilities and Shareholders Equity averaged around $12.9 million, with its median value being $13.8 million (2023).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 72389.61% in 2022, then crashed by 6128.12% in 2025.
  • BioRestorative Therapies' Liabilities and Shareholders Equity (Quarter) stood at $22.5 million in 2021, then fell by 26.81% to $16.4 million in 2022, then decreased by 23.26% to $12.6 million in 2023, then dropped by 2.63% to $12.3 million in 2024, then tumbled by 54.05% to $5.6 million in 2025.
  • Its Liabilities and Shareholders Equity was $5.6 million in Q3 2025, compared to $8.5 million in Q2 2025 and $10.3 million in Q1 2025.